These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25007369)

  • 1. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies.
    Levin AA; Gottlieb AB; Au SC
    J Drugs Dermatol; 2014 Jul; 13(7):848-53. PubMed ID: 25007369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
    Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of biologics in psoriasis: a review.
    Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
    Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of psoriasis: the impact of private versus public insurance.
    Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
    Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
    Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
    Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
    van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
    Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
    Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
    J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
    [No Abstract]   [Full Text] [Related]  

  • 14. Switching of biologics in psoriasis: Reasons and results.
    Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug survival rates in patients with psoriasis after treatment with biologics.
    Umezawa Y; Nobeyama Y; Hayashi M; Fukuchi O; Ito T; Saeki H; Nakagawa H
    J Dermatol; 2013 Dec; 40(12):1008-13. PubMed ID: 24304288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
    Armstrong AW; Foster SA; Comer BS; Lin CY; Malatestinic W; Burge R; Goldblum O
    BMC Dermatol; 2018 Jun; 18(1):4. PubMed ID: 29954363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Biologic and Conventional Systemic Therapies in Adults with Chronic Plaque Psoriasis in Daily Practice: A Systematic Review.
    Zweegers J; Otero ME; van den Reek JM; van Lümig PP; Driessen RJ; Kievit W; Seyger MM; van de Kerkhof PC; de Jong EM
    Acta Derm Venereol; 2016 May; 96(4):453-8. PubMed ID: 26537336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug survival rates and reasons for drug discontinuation in psoriasis.
    Arnold T; Schaarschmidt ML; Herr R; Fischer JE; Goerdt S; Peitsch WK
    J Dtsch Dermatol Ges; 2016 Nov; 14(11):1089-1099. PubMed ID: 27879076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic therapy in erythrodermic and pustular psoriasis.
    Levin EC; Debbaneh M; Koo J; Liao W
    J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.